Latest Announcements

Sharp Investments Ltd has intimated a Board Meeting on June 26, 2026, to consider an initial investment via the acquisition of equity shares in Rajal Lefin & Commercial Private Limited (RLCPL). The board will also discuss the broad framework of the proposed acquisition, including the percentage of shares, acquisition mode, and consideration, and approve the appointment of necessary advisors. The trading window for designated persons will remain closed until 48 hours post-meeting.

Transrail Lighting Ltd announced the acquisition of 100% equity stake in Gactel Turnkey Projects Limited, a fellow subsidiary, for cash consideration. This strategic move aims to strengthen Transrail's cooling tower engineering, execution, and maintenance capabilities, enhancing its end-to-end EPC offerings and supporting future growth despite Gactel's small FY26 turnover of ₹0.58 Crore. The transaction is a related party deal but is stated to be at arm's length based on an independent valuation. Concurrently, the Board noted the resignation of Mr. Raman Rajagopalan, Deputy Managing Director, effective July 31, 2026, due to personal commitments.

Transrail Lighting Limited announced two key decisions: the acquisition of 100% equity in Gactel Turnkey Projects Limited and the resignation of Deputy Managing Director Mr. Raman Rajagopalan. The acquisition of Gactel, a company with a FY26 turnover of ₹0.58 Crore in industrial cooling solutions, is a strategic cash investment aimed at bolstering Transrail's engineering and EPC capabilities in cooling towers. While a related party transaction, it's stated to be at arm's length. Mr. Rajagopalan's resignation, effective July 31, 2026, is due to personal commitments. The acquisition signals future growth in a niche segment.

Transrail Lighting Ltd announced the approval for acquiring a 100% equity stake in Gactel Turnkey Projects Limited, an industrial cooling solutions provider, for cash consideration. This strategic acquisition aims to bolster Transrail's cooling tower engineering and EPC capabilities, despite Gactel reporting a low turnover of ₹0.58 Crore for FY2025-26. The transaction is a related party transaction but stated to be at arm's length based on an independent valuation. Additionally, the company noted the resignation of Mr. Raman Rajagopalan, Deputy Managing Director, effective July 31, 2026, due to personal commitments.

Transrail Lighting Limited is set to acquire a 100% equity stake in Gactel Turnkey Projects Limited, an Industrial Cooling Solutions provider, from Ajanma Holdings Private Limited. This strategic acquisition, despite Gactel's FY26 turnover of ₹0.58 Crore, aims to strengthen Transrail's engineering and EPC capabilities in cooling towers and industrial chimneys and support future growth. The transaction is a related party deal but is stated to be at arm's length. Additionally, Mr. Raman Rajagopalan has resigned as Deputy Managing Director for personal reasons, effective July 31, 2026.

Transrail Lighting Ltd announced the acquisition of 100% equity stake in Gactel Turnkey Projects Limited for cash consideration. This strategic move aims to strengthen Transrail's cooling tower engineering and execution capabilities, enhance end-to-end EPC services, and support future growth in related businesses. Gactel, a fellow subsidiary with a turnover of ₹0.58 Crore in FY2025-26, will be acquired via a related-party transaction, stated to be at arm's length based on an independent valuation. Additionally, the company noted the resignation of Mr. Raman Rajagopalan as Deputy Managing Director, effective July 31, 2026, due to personal commitments.

Nava Ltd's Board has approved the amalgamation of its wholly-owned subsidiary, Nava Healthcare Pte. Ltd. (NHPL), with another wholly-owned subsidiary, Nava Global Pte. Ltd. (NGPL), subject to Singapore regulatory approvals. This internal reorganization aims to consolidate the Group's investments (excluding commercial agriculture and O&M services) under one platform. NGPL will oversee a restructured healthcare investment, facilitating expansion into value-added healthcare services and other growth opportunities in South East Asia. NHPL, with an income of Rs. 279 lakhs, is being merged into NGPL, which has an income of Rs. 1,05,914 lakhs, as of March 31, 2026.

Zota Health Care Limited has acquired 1,000,000 equity shares of its wholly-owned subsidiary, Curexis Ventures Private Limited, for Rs. 2 crore through a rights issue subscription. This strategic investment aims to expand Curexis's SKIA retail pharmacy stores and address its working capital needs. Curexis, engaged in drug manufacturing, development, and marketing, will continue as a wholly-owned subsidiary post-acquisition. The subsidiary reported a turnover of Rs. 1.18 lakhs in FY2025-26. The transaction was a cash consideration.

BN Agrochem Ltd has received an order dated June 19, 2026, from the Hon'ble National Company Law Tribunal (NCLT), Mumbai Bench. This order directs the company to convene a meeting of its equity shareholders. The purpose of this meeting is to consider and approve a Scheme of Amalgamation involving BN Agrochem Limited and three transferor companies: Al Agri Global Limited, B.N. Agritech Limited, and Salasar Balaji Overseas Private Limited. The amalgamation aims for operational integration, cost reduction, and better facility utilization.

Noize Brands and Lifestyle Limited has acquired an additional 1,55,860 equity shares of Jauss Polymers Ltd through an off-market transfer, representing 3.36% of the company's total paid-up equity share capital. This acquisition increases Noize Brands' total shareholding from 40.04% to 43.41%. The acquirer is not part of the promoter group, and the disclosure was made under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Yash Hitesh Patel, along with Persons Acting in Concert, acquired an additional 3.95% stake in Nanta Tech Ltd through open market purchases on June 11, 2026. This transaction increased their total shareholding from 17.41% (8,93,400 shares) to 21.36% (10,95,600 shares) of the company's total equity share capital. The acquirer group explicitly stated they do not belong to the promoter/promoter group. This disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Hubtown Ltd has submitted the Scrutinizer's Report and voting results for the equity shareholders' meeting held on June 19, 2026. The meeting, convened by the NCLT, approved a Scheme of Arrangement for the merger/amalgamation of 25 West Realty Private Limited with Hubtown Limited. The resolution passed with overwhelming support, with 99.99% to 100% of votes cast by both promoter and public shareholders in favor, signaling progress on this strategic corporate action.

Hubtown Limited announced that its equity shareholders have approved the Scheme of Arrangement for the merger/amalgamation of 25 West Realty Private Limited with Hubtown Limited. The Court Convened General Meeting, held on June 19, 2026, saw the resolution pass with an overwhelming majority, receiving 99.99% of votes in favor from the total polled votes. This approval, pursuant to NCLT directions, marks a crucial step in the corporate restructuring process.

Suraj Industries Ltd. has completed the acquisition of equity shares in Carya Chemicals & Fertilizers Private Limited by converting an outstanding unsecured loan of approximately ₹25 crore into 1,05,04,201 equity shares at an issue price of ₹23.80 each. This transaction increases Suraj Industries' shareholding in CARYA from 95.44% to 96.06%, thereby enhancing control over its material subsidiary. CARYA, operating in the breweries and distilleries sector, has commenced commercial operations of its bottling plant and is constructing a distillery. The acquisition, confirmed as a related-party transaction, was executed at arm's length based on a valuation report and received necessary approvals.

Balkrishna Namdeo Salunkhe, a promoter of Jaro Institute of Technology Management and Research Ltd, acquired 4,55,098 equity shares via an off-market transaction on June 9, 2026. This acquisition increased his shareholding from 2.05% (4,57,098 shares) to 4.10% (9,12,196 shares) of the company's total equity. The disclosure was made in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Aurobindo Pharma USA, a wholly-owned subsidiary of Aurobindo Pharma Limited, has received U.S. Federal Trade Commission (FTC) approval to acquire Lannett Company LLC for $250 million. This acquisition, set to close by June 2026, will significantly expand Aurobindo's portfolio of complex generic and non-opioid controlled substances and add a U.S.-based manufacturing facility. The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share and generate meaningful cost efficiencies and synergies, supporting sustainable long-term growth.

Aurobindo Pharma USA, a wholly-owned subsidiary of Aurobindo Pharma Ltd, has received U.S. Federal Trade Commission (FTC) approval to acquire Lannett Company LLC for $250 million. This acquisition significantly expands Aurobindo's product offering in complex, non-opioid controlled substances and adds a U.S.-based manufacturing facility. The transaction, expected to close by end of June 2026, is anticipated to be immediately accretive to the Aurobindo Group's earnings per share. It is also projected to generate meaningful cost efficiencies, SG&A synergies, and enhance the company's differentiated pipeline for sustainable long-term growth.